TME PHARM.CONF.IPO EO 1- Asset Resilience Ratio
TME PHARM.CONF.IPO EO 1- asset resilience ratio. TME PHARM.CONF.IPO EO 1- (0N6A) has an Asset Resilience Ratio of 0.19% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of TME PHARM.CONF.IPO EO 1- to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of TME PHARM.CONF.IPO EO 1- (2021–2025)
Asset resilience ratio of TME PHARM.CONF.IPO EO 1- from 2021 to 2025. This chart shows how TME PHARM.CONF.IPO EO 1-'s Asset Resilience Ratio has changed over time. Read 0N6A total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down TME PHARM.CONF.IPO EO 1-'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TME PHARM.CONF.IPO EO 1- total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €4.00K | 0.19% |
| Total Liquid Assets | €4.00K | 0.19% |
Asset Resilience Insights
- Limited Liquidity: TME PHARM.CONF.IPO EO 1- maintains only 0.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
TME PHARM.CONF.IPO EO 1- Industry Peers by Asset Resilience Ratio
Compare TME PHARM.CONF.IPO EO 1-'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
TME PHARM.CONF.IPO EO 1- Asset Resilience Ratio by Year (2021–2025)
TME PHARM.CONF.IPO EO 1- asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for TME PHARM.CONF.IPO EO 1-.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.19% | €4.00K ≈ $4.68K |
€2.14 Million ≈ $2.50 Million |
+0.04pp |
| 2024-12-31 | 0.15% | €5.00K ≈ $5.85K |
€3.41 Million ≈ $3.98 Million |
-0.14pp |
| 2021-12-31 | 0.29% | €28.00K ≈ $32.73K |
€9.77 Million ≈ $11.42 Million |
-- |
About TME PHARM.CONF.IPO EO 1-
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indicatio… Read more